INTRODUCTION {#s1}
============

Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that results from a genetic event or series of events occurring in an early hematopoietic precursor that both blocks differentiation and allows uncontrolled proliferation. The abnormally proliferating leukemic cells accumulate in the marrow space, eventually replacing normal marrow progenitors, with consequent diminished production of red cells, white cells, and platelets. This, in turn, leads to the common clinical manifestations of AML.^[@B1]^

The myelodysplastic syndromes (MDS) include a large spectrum of clonal hematopoietic stem cell disorders that are characterized by peripheral cytopenia(s), morphologic dysplasia, ineffective hematopoiesis, and a variable propensity to transform to AML.^[@B2]^

Granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates multipotent progenitor cells depending on its concentration. First, it stimulates the proliferation of macrophage progenitors, which is followed by granulocyte, erythroid, eosinophil, megakaryocyte, and multipotent progenitors. It also stimulates the differentiation of myeloid leukemic cells and controls eosinophil function in some instances.^[@B3]^

The human *GM-CSF* gene is approximately 2.5 kilo-base pairs. The gene is located on the long arm of chromosome 5 (5q21--q32). It has four exons that are separated by three introns.^[@B4]^ In addition to *GM-CSF*, genes encoding various cytokines such as IL4, IL5, IL9, IL12, M-CSF, and the *EGR1* gene are located at the 5q31.1 locus of chromosome 5.^[@B5]^ The 5q− syndrome has elucidated the role of these cytokines in development of clonal hematopoietic stem cells.^[@B6]^ The current study aimed to investigate and understand the role of GM-CSF in the pathogenesis, progression, and response to therapy in Egyptian patients with AML/MDS.

PATIENTS AND METHODS {#s2}
====================

Study Population {#s3}
----------------

This study is an observational descriptive study and included 50 patients with AML/MDS. Patients were recruited from the outpatient clinic and the inpatient wards of Kasr Al Ainy Clinical Hematology Unit, Internal Medicine Department, and Clinical Oncology Department, Faculty of Medicine, Cairo University.

Patients in complete remission (CR) or those with a history of recombinant human GM-CSF intake were excluded. Twenty age- and sex-matched healthy volunteers were included in the study as a control group. The study was approved by the Research Ethical Committee of the Internal Medicine Department, Faculty of Medicine, Cairo University, and informed consent was obtained from all participants before enrollment in the study.

For the control subjects, a 4-mL EDTA blood sample was collected under completely aseptic conditions for molecular studies.

Patients' samples at first presentation (either peripheral blood or bone marrow aspirated on EDTA and serum samples) were collected under completely aseptic conditions for molecular studies and enzyme-linked immunosorbent assay (ELISA) techniques, respectively.

Quantitative Assessment of *GM-CSF* Gene Expression {#s4}
---------------------------------------------------

Extraction of total RNA was performed by QIAamp RNA Blood Mini Kit (QIAGEN, Hilden, Germany), according to the manufacturer's instructions. Total RNA was reverse transcribed using random primers with a high-capacity cDNA archive kit (Applied Biosystems, Foster City, CA).

*GM-CSF* gene expression was detected by real-time polymerase chain reaction on the basis of TaqMan technology using ABI Prism 7700 (Applied Biosystems.

The primers and probes for *GM-CSF* as well as the housekeeping gene *GAPDH* were provided by QIAGEN and were as follows. *GM-CSF* gene: forward primer 5′-CTGCTGAGATGAATGAAACAG-3′ and reverse primer 5′-TCCAAGATGACCATCCTGAG-3′; FAM (6-carboxy fluorescein) probe 5′-ACTCCCACCATGGCTGTGG-3′ (TaqMan GM-CSF, access no. M11220, Applied Biosystems). The thermocycler program conducted was initial denaturation at 50°C for 2 minutes followed by 40 cycles of denaturation at 95°C for 10 minutes, annealing at 95°C for 0.15 minute, and extension at 60°C for 1 minute. The relative quantification of gene expression was assessed by the 2^−ΔΔCt^ method (ΔΔCt = {\[Ct (*GM-CSF* sample) − Ct (*GAPDH* sample)\] − \[Ct (*GM-CSF* calibrator) − Ct (*GAPDH* calibrator)\]}. The calibrator was the average ΔCt value of 20 controls.^[@B7]^

Assessment of GM-CSF Protein and Anti--GM-CSF Antibodies {#s5}
--------------------------------------------------------

The concentration of GM-CSF protein was measured in appropriately diluted sera from all patients with AML/MDS as well as healthy controls by using a specific ELISA assay (Quantikine human GM-CSF kit, catalog no. SGM00; R&D Systems, Minneapolis, MN). The minimum detectable dose of GM-CSF by this reagent is typically \< 3 pg/mL.

The concentration of GM-CSF antibodies was measured in appropriately diluted sera from 42 patients with AML/MDS as well as healthy controls by using a specific ELISA assay (anti--GM-CSF Ab kit, catalog no. MBS162797; MyBioSource, San Diego, CA). The minimum detectable dose of GM-CSF antibodies by this reagent is typically \< 0.52 ng/mL.

Treatment Regimen and Response to Therapy {#s6}
-----------------------------------------

All patients were treated according to the adopted protocol of the Internal Medicine Department, Faculty of Medicine, Cairo University. Patients with AML (except subtype M3 cases) were subjected to the 7-3 protocol for induction of remission. Subtype M3 patients were subjected to all-*trans*-retinoic acid. Treatment of AML depends on the fitness of the patient. Fit patients (\< 60 years old) received intensive therapy. Treatment includes induction and postremission therapy (consolidation). Less fit patients (70 to 75 years and older, or younger patients with significant comorbidities) receive low-intensity therapy. For induction therapy, a combination of cytarabine and anthracycline or anthracenedione is recommended (cytarabine 100 to 200 mg/m^2^ continuous intravenous infusion for 7 days plus idarubicin 12 mg/m^2^/day for 3 days or daunorubicin 60 to 90 mg/m^2^/day for 3 days). Follow-up by bone marrow examination to assess remission is typically done 7 to 14 days after completion of induction chemotherapy. For postremission therapy, all patients should be assessed for risk of relapse. Specific drug regimens are recommended on the basis of a patient's risk of relapse (eg, high-dose cytarabine 3 g/m^2^ intravenously over 3 hours every 12 hours on days 1, 3, and 5 for four cycles).

CR status is defined by normalization of the neutrophil count (≥ 1.5/μL) and platelet count (\> 100 × 10^3^/mm^3^), and marrow examination that demonstrates ≥ 20% cellularity, \< 5% blasts and no Auer rods, as well as absence of extramedullary infiltration. Resistance to treatment is defined as \> 25% blasts in the bone marrow, lack of regeneration of normal hematopoiesis, persistence of peripheral blood blasts, and/or extramedullary leukemia after induction. Relapse is defined as re-infiltration of the bone marrow by ≥ 5% leukemic blasts or proven leukemic blasts at any site. Death during induction is defined as death during or after the first course of therapy with aplastic or hypocellular marrow.^[@B8]^

The only known curative modality for patients with MDS is stem-cell transplantation. Therefore, all appropriate candidates should be considered for stem-cell transplantation. They include patients younger than 70 years, with a reasonable performance status and no significant comorbidity ([Fig 1](#F1){ref-type="fig"}).

![Algorithm for management of a patient with myelodysplastic syndrome (MDS). ATG, antithymocyte globulin; EPO, erythropoietin; G-CSF, granulocyte-colony stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HLA D15, human leukocyte antigen-D15; int 1, Intermediate-1; IPSS, International Prognostic Scoring System; MDS-U, myelodysplastic syndromes-unclassifiable; PNH, paroxysmal nocturnal hemoglobinuria; PS, performance status; RA, refractory anemia; RARS, refractory anemia with ring sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-T, refractory cytopenia with multilineage dysplasia in transformation; rhu-EPO, recombinant human erythropoietin; RIC, reduced-intensity conditioning regimen; SCT, stem-cell transplantation.](JGO.2017.009332f1){#F1}

Data Analysis {#s7}
-------------

Data were analyzed using IBM SPSS advanced statistics version 20 (SPSS, Chicago, IL). Numerical data of scores were expressed as the mean and standard deviation or the median and range, as appropriate. Qualitative data were expressed as number and percentage. Data distribution is not normal (the skewness and kurtosis SPSS was used). Statistical differences between groups were tested using the χ^2^ test for qualitative variables. The Spearman-ρ method was used to test correlations between numeric variables. Survival analysis was done using the Kaplan-Meier method and comparison between two survival curves was done using the log-rank test. A *P* value \< .05 was considered significant.

RESULTS {#s8}
=======

Twenty-seven of 50 patients (54%) were men and 23 of 50 (46%) were women. Their ages ranged from 20 to 91 years, with a median of 45.5 years. According to disease subtypes, 44 patients (88%) had AML and six patients (12%) had MDS. According to the French-American-British classification of AML, 14 patients (28%) were subtype M1, nine (18%) were M2, three (6%) were M3, nine (18%) were M4, four (8%) were M5, and five (10%) were M7. According to the Revised International Prognostic Scoring System (IPSS-R) for MDS risk assessment, three patients (50%) had intermediate IPSS-R category, two patients (33.3%) had low IPSS-R category, and one patient (16.6%) had very low IPSS-R category. Seventeen patients did not receive chemotherapy as the result of bad general condition, poor performance, or refusal. Among patients with AML who received chemotherapy, the CR rate was 15 of 33 patients (45.4%), the failure of induction rate was six of 33 (18.1%), and the mortality rate was 12 of 33 (36.36%). Of 15 patients who achieved CR, relapse was reported in five of them (33.3%) after follow up of 24 months. Overall survival (OS) ranged from 1 to 24 months, with a mean of 4 ± 4.04 months. The OS for patients who achieved CR ranged from 2 to 12 months, with a mean of 7.6 ± 3.8 months.

*GM-CSF* Gene Expression {#s9}
------------------------

*GM-CSF* gene expression values in the 20 healthy controls ranged from 0.659 to 1.515, with a mean value of 0.62 ± 0.09 and a median value of 1.01. In the 50 patients with AML/MDS, *GM-CSF* gene expression values ranged from 0.0126 to 3.249, with a mean value of 0.629 ± 0.09 and a median value of 1.8. *GM-CSF* gene expression levels were significantly lower in patients with AML/MDS compared with controls (*P* = .008). We did not find significant correlations between *GM-CSF* gene expression and age, sex, clinical data, total leukocytic count, initial peripheral blood (PB) blasts percentage, treatment outcome, length of CR, and OS ([Table 1](#T1){ref-type="table"}).
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GM-CSF Protein and Anti--GM-CSF Antibodies {#s10}
------------------------------------------

Serum GM-CSF protein concentrations in the healthy controls ranged from 7 to 8.6 pg/mL, with a mean of 7.6 ± 0.8 pg/mL and a median of 7.8 pg/mL. In the 50 patients with AML/MDS, serum GM-CSF protein concentrations ranged from 12 to 80 pg/mL, with a mean of 41.1 ± 18.4 pg/mL and a median of 40 pg/mL. We found higher GM-CSF protein concentrations in patients with AML/MDS compared with controls (*P* \< . 001). We found a significant negative correlation between GM-CSF protein concentrations and initial PB blasts percentage (r = −0.357, *P* = .011) and treatment outcome (r = −0.339, *P* = .016). Otherwise, we did not find significant correlations between GM-CSF protein concentrations and age, sex, clinical data, other laboratory data, period of CR, and OS ([Table 1](#T1){ref-type="table"}).

Concentrations of serum anti--GM-CSF antibodies in the healthy controls ranged from 10 to 18 ng/mL, with a mean of 14 ± 4 ng/mL and a median of 14 ng/mL. In 42 of 50 patients with AML/MDS (84%), concentrations of serum anti--GM-CSF antibodies ranged from 37 to 240 ng/mL, with a mean of 64.4 ± 42.33 ng/mL and a median of 46 ng/mL. We found higher concentrations of serum anti--GM-CSF antibodies in patients with AML/MDS compared with controls (*P* = .001). We did not find significant correlations between concentrations of serum anti--GM-CSF antibodies and age, sex, clinical data, laboratory data, treatment outcome, period of CR, and OS ([Table 1](#T1){ref-type="table"}).

Response to Therapy in Patients With AML/MDS {#s11}
--------------------------------------------

After a 24-month observation period for the 38 patients who survived, the mean survival time was 4 ± 4.04 months (range, 1 to 24 months), with a median of 12 months. The mean CR was 7.6 ± 3.8 months (range, 2 to 12 months), with a median of 7 months.

In patients who did not receive chemotherapy, the mean survival time was 4.2 ± 2.4 months, with a median of 5 months. In patients who received chemotherapy, the mean survival time was 8.2 ± 4.5 months, with a median of 4 months. There was a highly significant association between mean survival time and receipt of chemotherapy (*P* = .006).

DISCUSSION {#s12}
==========

Growth and progression of leukemic cells are mediated by alterations in the microenvironment, which are often caused by an aberrant expression of growth factors and receptors.^[@B9]^ GM-CSF is an autocrine/paracrine cytokine that stimulates growth, differentiation, and function of normal and leukemic myeloid progenitors. Antibodies to GM-CSF are also implicated in the process of leukemogenesis.

This study aimed to investigate the roles of *GM-CSF* gene expression, serum GM-CSF protein concentrations, and levels of anti--GM-CSF antibodies in patients with AML/MDS in relation to treatment outcome and OS, to help understand their impact on the pathogenesis of the disease and hence predict prognosis, as well as response to treatment.

This study revealed that *GM-CSF* gene expression levels were significantly lower in patients with AML/MDS compared with controls. This is in accordance with previous studies,^[@B10],[@B11]^ which reported that *GM-CSF* gene expression measured by real-time polymerase chain reaction was lower in patients with leukemia than in healthy volunteers. Also, it has been demonstrated that in vivo autocrine production of GM-CSF is not common in unperturbed AML, but allows the possibility that either autocrine or paracrine GM-CSF activity could be induced in leukemic cells under stress conditions.^[@B12]^ Furthermore, abnormalities in *GM-CSF* gene expression levels may contribute to the pathogenesis and abnormal proliferation of leukemia.^[@B13],[@B14]^

In the current study, serum GM-CSF protein concentration was significantly higher in patients with AML/MDS compared with controls. This is in accordance with previous reports.^[@B15],[@B16]^ Highly significant increases in serum levels of GM-CSF were previously reported in 14 Egyptian patients with AML compared with the reference control group.^[@B17]^ This was in contrast to results from another study, which reported comparable concentrations of serum GM-CSF in patients with AML and healthy controls.^[@B11]^

The current finding of a negative correlation between serum levels of GM-CSF and initial PB blasts percentage could be correlated to defects in the biologic functions of GM-CSF. These may be attributed to a functional alteration of the GM-CSF receptor or disturbances of signal transduction pathways, which need larger future studies. Furthermore, a lower serum level of GM-CSF was associated with better response to therapy, which suggests that GM-CSF protein concentration could be used as a biomarker to predict the outcome of therapy in AML/MDS cases.

In this study, higher levels of GM-CSF antibodies were found in patients with AML/MDS compared with controls. Our results are in agreement with a previous study that reported a high prevalence of anti--GM-CSF antibodies in patients with myeloid leukemia and MDS and a higher titer of GM-CSF antibodies in patients with active disease compared with patients in CR.^[@B11]^

In conclusion, our results suggest that *GM-CSF* expression levels may have implications in leukemogenesis. The use of GM-CSF protein levels and GM-CSF antibodies as prognostic markers of disease activity needs further investigation.
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